ENDRA Life Sciences Adds Five New International Patents to its IP Portfolio

ENDRA Life Sciences Inc.’s intellectual property portfolio has reached an 80-patent milestone, thanks to the recent awarding of five new patents—three in Europe and two in China—for its TAEUS system thermoacoustic technology.   

“With the issuance of these five patents, we’ve reached a significant milestone of 80 global patents,” ENDRA Chairman/CEO Francois Michelon said. “Our IP portfolio safeguards and sets apart ENDRA’s thermoacoustic technology in areas of high unmet clinical need. We’re actively enhancing our intellectual property to secure our technology in key global markets and exploring licensing opportunities for indications beyond our core focus, opening further growth avenues for the company.”
 
The following five patents were issued:

• European Patent No. EP4051151: “Radio Frequency Applicator and Thermoacoustic Imaging System Employing the Same,” covers a radio frequency (RF) applicator device and system for providing reliable RF energy to a target area of tissue. Specifically, this patent structurally defines ENDRA’s solution to providing RF energy to targeted tissue regions for applications, such as liver fat quantification.
• European Patent No. EP4037554: “Method and System for Determining a Material Type of an Object of Interest,” protects ENDRA’s method and system for determining a material type by utilizing TAEUS. The patent has potential application beyond liver measurements, which may include outside the human body.
• European Patent No. EP4037551: “Method and System for Determining a Parameter of a Material of Interest,” relates to a novel method for determining at least one parameter of interest of a material utilizing TAEUS. Examples of potential parameters of interest include the Grüneisen parameter, which is the ratio of thermal pressure to thermal energy and conductivity. In addition, this patent expands the imaging potential for the TAEUS technology outside the human body for select applications, such as material testing and identification.
• Chinese Patents ZL2019800868227 and ZL202110813939X: “Method and System for Monitoring Tissue Temperature,” both patents relate to novel methods and systems for monitoring tissue temperature with TAEUS during surgical procedures such as thermotherapy and cryotherapy.

ENDRA Life Sciences’ Thermo Acoustic Enhanced UltraSound (TAEUS) technology characterizes tissue like MRI, but at 1/40th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 700,000 ultrasound systems currently in use globally. TAEUS is initially focused on the measuring liver fat to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects more than 2 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature imaging during energy-based surgical procedures.

ENDRA Life Sciences is based in Ann Arbor, Mich., and has offices/facilities in England, France, Germany, and The Netherlands.